Federal judge blocks HHS rule requiring list prices in drug TV ads

Drug prices
A federal judge sided with drugmakers Monday, blocking a Trump administration rule to require list prices be included in their TV ads. (Getty/Tero Vesalainen)

A federal judge sided with drugmakers Monday, blocking a Trump administration rule to require list prices be included in their TV ads.

The Centers for Medicare & Medicaid Services (CMS) announced the rule in May that would require drug manufacturers that sell drugs covered by Medicare and Medicaid to include the cost for a typical course of treatment, such as a 30-day supply of medication for a chronic condition, in their TV ads.

Merck & Co., Eli Lilly and Amgen, along with the Association of National Advertisers, sued the Department of Health and Human Services (HHS) and CMS to block the rule they call unnecessary and unlawful. The rule was set to take effect July 9.

Research

Learn What 1,000 People Said About Their Virtual Care Experiences During COVID-19

72% of patients had their first virtual visit during the pandemic and most now want it as a permanent option. Learn what else our survey revealed about their experiences with virtual visits, preferences for scheduling them, and more.

In his decision, U.S. District Judge Amit Mehta for the U.S. District Court for the District of Columbia said the HHS rule would exceed the agency’s statutory authority, even as he clarified he was not opining on HHS' motives for adopting the rule. 
 
"That policy very well could be an effective tool in halting the rising cost of prescription drugs," Mehta wrote. "But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized."
 
He also said the policy "is far afield of any other type of rulemaking authority HHS has previously exercised" under the Social Security Act and that it would have far broader policy implications.

HHS spokeswoman Caitlin Oakley said the agency is "disappointed" with the court's decision and will work with the Department of Justice on next steps related to the litigation.

"President Trump and Secretary Azar remain focused on lowering drug prices and empowering patients through more transparency in healthcare costs," Oakley said. "Although we are not surprised by the objections to transparency from certain special interests, putting drug prices in ads is a useful way to put patients in control and lower costs, and as seen from the President’s executive order, we are working on many different avenues for delivering transparency."

Suggested Articles

While the COVID-19 pandemic has wreaked financial havoc across healthcare, it did not stymie mergers and acquisition deals as much as anticipated.

Some labs are starting to reach capacity for COVID-19 testing amid a major spike in cases across sunbelt states, HHS reported.

Health technology continues to be one of the bright spots during the economic downturn. Here's how much investors poured into the market in 2020.